{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
GeoVax Labs, Inc.
Is GeoVax Labs, Inc. overvalued or undervalued?
As of November 12, 2024, GeoVax Labs, Inc. is rated as risky due to overvaluation and poor financial metrics, including a Price to Book Value of 2.15 and a year-to-date return of -73.22%, significantly underperforming the S&P 500.
Is GeoVax Labs, Inc. overvalued or undervalued?
As of November 12, 2024, GeoVax Labs, Inc. is considered overvalued and risky due to troubling financial metrics, including a Price to Book Value of 2.15 and negative earnings performance, alongside a year-to-date decline of 64.58%, significantly underperforming the S&P 500's 2.44% gain.
Who are in the management team of GeoVax Labs, Inc.?
As of March 2022, the management team of GeoVax Labs, Inc. includes Mr. David Dodd as Chairman, President, and CEO, along with Directors Dr. Robert McNally, Dr. Randal Chase, Mr. Dean Kollintzas, and Mr. John Spencer.
What does GeoVax Labs, Inc. do?
GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing human vaccines for infectious diseases. It has a market cap of $14.33 million, with recent net sales of $2 million and a net loss of $5 million.
How big is GeoVax Labs, Inc.?
As of Jun 18, GeoVax Labs, Inc. has a market capitalization of 14.33 million, with net sales of 5.59 million and a net profit of -24.50 million over the latest four quarters. The company's shareholder's funds are 5.05 million, and total assets are 8.16 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
